Zheng Quan Zhi Xing·2025-07-30 16:37Core Viewpoint - The report outlines the qualification verification process conducted by China International Capital Corporation (CICC) for the share transfer of Sinovac Biotech Ltd. to specific institutional investors, confirming that the transferring party meets the necessary regulatory requirements [1][5]. Group 1: Transfer Delegation - CICC has received a mandate from Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to organize the share transfer of Sinovac Biotech [1]. - The transfer is being conducted in accordance with relevant regulations, including the implementation opinions for the Sci-Tech Innovation Board and the self-regulatory guidelines for share transfers [1]. Group 2: Verification of Qualifications - CICC completed the qualification verification of the transferring party, which included checking the business license and other relevant documents [2]. - The transferring party, Shenzhen Keyi, is a limited liability company established on October 9, 2018, with a business scope that includes investment in the pharmaceutical industry [2]. Group 3: Compliance with Regulations - CICC confirmed that the transferring party has not encountered any legal or regulatory issues that would terminate its business operations [2]. - The report details compliance with specific guidelines regarding share reduction by major shareholders and actual controllers, ensuring that no prohibited circumstances exist for the share transfer [3][4]. Group 4: Conclusion of Verification - CICC concludes that the transferring party meets the conditions for participating in the share transfer, having adhered to all relevant regulations and guidelines [5].